Raymond James Downgrades MacroGenics (MGNX) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts MGNX Hot Sheet
Price: $2.40 +0.84%
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Raymond James analyst Reni Benjamin downgraded MacroGenics (NASDAQ: MGNX) from Outperform to Underperform.
For an analyst ratings summary and ratings history on MacroGenics click here. For more ratings news on MacroGenics click here.
Shares of MacroGenics closed at $16.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades First Busey (BUSE) to Market Perform
- Raymond James Downgrades Alnylam Pharmaceuticals (ALNY) to Outperform
- Stifel Downgrades Acumen Pharmaceuticals, Inc. (ABOS) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
